Everest Organics Faces Capacity Approval Going-Concern Risk

Everest Organics Limited received a qualified limited-review report for the quarter and half year ended 30 September 2026 after auditors said production was substantially above approved capacity without required pollution-control approvals, a non-compliance that could bring a closure order and affect going-concern status. Quarterly sales were Rs 48.3789 crore.

Why did Everest Organics receive a qualified limited review?

Everest Organics received the qualification because it was operating at a substantially enhanced actual production level beyond the capacity specified in a 22 November 2017 order of the Telangana State Pollution Control Board, or TSPCB. The qualified report, dated 12 November 2026, covers the quarter and half year from 1 April 2026 to 30 September 2026.

The auditors said a TSPCB revocation order dated 4 February 2022, connected with a 22 December 2020 closure order, stipulated that Everest Organics could not exceed the capacity in the 2017 order. The filing does not state either the approved production capacity or the actual level of enhanced production, so the extent of the excess cannot be quantified from the disclosure.

The review was performed under Standard on Review Engagements 2410, which the auditors said provides moderate assurance and is substantially less extensive than an audit. Subject to the capacity-related qualification, the auditors said nothing had come to their attention to suggest that the 30 September 2026 financial results failed to make required disclosures or contained a material misstatement.

How could the capacity issue affect Everest Organics operations?

The capacity issue could affect Everest Organics operations because the auditors said the non-compliance could impair its going-concern status through a closure order from TSPCB. This was described as a potential regulatory consequence in the 12 November 2026 report, not confirmation that TSPCB had issued a new closure order for the September 2026 period.

The auditors identified two approvals required for the enhanced capacity: Consent for Establishment, or CFE, for the expanded establishment, followed by Consent for Operation, or CFO. Everest Organics was producing at the enhanced level without these approvals, according to the qualification, despite the capacity restriction carried in the 4 February 2022 revocation order.

The filing distinguishes an Environmental Clearance Certificate from the TSPCB permissions cited by the auditors. Management said Everest Organics had obtained environmental clearance for additional capacity, but its CFE application for the enhanced capacity was pending as of 12 November 2026. The source gives no application date, decision timetable or indication that a CFO application had been approved.

What is Everest Organics doing to resolve the approval gap?

Everest Organics told the auditors that management was addressing the matter and had applied for a CFE for the enhanced capacity, with the application pending on 12 November 2026. This pending application, together with the Environmental Clearance Certificate for additional capacity, is the only remedial action disclosed in the limited-review report.

The pending CFE did not remove the qualification from the results for the period ended 30 September 2026. The auditors explicitly stated that their limited-review report was qualified on this matter, because the subsequent CFO identified in the report had not been disclosed as obtained.

The source does not say whether TSPCB has requested further information, imposed conditions or communicated an approval deadline. It also provides no plan to reduce production to the capacity set by the 22 November 2017 order while the CFE remains pending.

What do Everest Organics sales and financial figures show?

Everest Organics reported Rs 48.3789 crore of sales turnover in the quarter ended 30 September 2026, consisting of Rs 43.7952 crore of domestic turnover and Rs 4.5837 crore of export turnover. The company has one reportable segment, active pharmaceutical ingredients, or API, and their intermediates.

Domestic turnover exceeded export turnover by Rs 39.2115 crore in the September 2026 quarter. The filing does not provide prior-period turnover in the sales note, so it does not support a quarter-on-quarter or year-on-year sales growth comparison for this disclosure.

Trade receivables increased to Rs 120.169 crore at 30 September 2026 from Rs 116.1601 crore at 31 March 2026, while current borrowings declined to Rs 39.5431 crore from Rs 42.6564 crore. Separately, Everest Organics said 263,157 warrants issued earlier at Rs 152 each received their remaining 75% subscription money during the September 2026 quarter.

The board approved the unaudited results on 12 November 2026 after audit committee review on the same date. Everest Organics also reported 176,870 equity shares in its Unclaimed Suspense Account as of 30 September 2026, a disclosure separate from the TSPCB capacity approval matter.

Conclusion

Everest Organics reported Rs 48.3789 crore of quarterly sales while its 30 September 2026 limited review was qualified over enhanced production without the TSPCB approvals identified by the auditors. The qualification does not quantify an adjustment to revenue, profit, assets or liabilities, but it directly identifies the possibility of a closure order and a resulting going-concern risk.

The next point to watch is the decision on Everest Organics' pending CFE application for expanded capacity and, after that, any CFO needed to operate at that capacity. Management said on 12 November 2026 that it was addressing the issue and had environmental clearance, but the filing does not disclose a regulatory timetable or resolution date.